Conclusion: When colonizes in esophagus, H. pylori increases the severity of esophageal inflammation and the incidence of BE and EA. The process may involve in the activation of NF-kB signaling pathway. Key Word(s): 1. esophagus; 2. NF-kB; 3. Helicobacter pylori; Presenting Author: SHU-JUN WANG Additional Authors: WEI-HONG WANG, YUN-XIANG CHU, GUI-GEN TENG Corresponding Author: WEI-HONG WANG
Affiliations: Peking University First Hospital Objective: To compare the efficacy of concomitant therapy for 7 days with standard triple therapy for 7 or 10 days in H. pylori eradication in China. Methods: 246 patients who were diagnosed as H. pylori infection by rapid urease test or 13C-urea breath test were included. All patients had never received Raf inhibitor eradication therapy. Patients were randomly divided into concomitant therapy for 7 days and standard triple therapy for 7 or 10 days. Concomitant therapy composed of esomeprazole (20 mg),
amoxicillin (1000 mg), clarithromycin (500 mg) and tinidazole (500 mg); all drugs were given twice a day. Standard triple therapy consisted of esomeprazole (20 mg), amoxicillin (1000 mg) and clarithromycin (500 mg); the drugs were given twice a day. The eradication rates were determined 4 weeks after the end of the treatment by 13C-urea ICG-001 in vivo breath test. The incidence of adverse reaction were recorded. Results: 242 of the 246 patients completed the follow-up. The intention-to-treat analyse (ITT) and the per-protocol analysis (PP) indicated that the concomitant therapy (91.4% and 92.5%) was superior to standard triple therapy for 7 days (79.3% and 81.2%) and 10 days (79.5% and 80.5%) (P < 0.05). The difference for the eradication rate between the standard triple therapy for 7 days and 10 days was not
significant (P > 0.05). There were no significant difference for the adverse reactions between the concomitant therapy (8.8%), standard triple therapy for 7 days (7.5%) and 10 days (9.8%) (P > 0.05). Conclusion: Concomitant therapy for 7 days is an effective and a safe strategy for H. pylori eradication and deserves consideration for the Selleck Gemcitabine initial eradication treatment in China. Key Word(s): 1. Helicobacter pylori; 2. eradication; 3. Concomitant therapy; Presenting Author: MARA BARBOSA Additional Authors: CARLA MARINHO, JOSE COTTER Corresponding Author: MARA BARBOSA Affiliations: Centro Hospitalar Do Alto Ave Objective: BACKGROUND: Subclinical hepatic encephalopathy (SHE) is characterized by a mild cognitive impairment. It is controversial if Helicobacter pylori infection has a role in SHE by contributing to the hyperammonemia that exists in cirrhosis. AIM: To assess the relationship between H. pylori infection, hyperammonemia and the presence of SHE in cirrhotic patients. Methods: METHODS: A prospective study was conducted. One-hundred and two cirrhotic outpatients were evaluated.